<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02392858</url>
  </required_header>
  <id_info>
    <org_study_id>2014-A01023-44</org_study_id>
    <nct_id>NCT02392858</nct_id>
  </id_info>
  <brief_title>Severe Influenza Cohort</brief_title>
  <acronym>ANTIGRIPPE</acronym>
  <official_title>Identification, in Patients Admitted to Intensive Care for Severe Influenza Respiratory Infection, of a Predictive Biomarker of Respiratory Distress</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospices Civils de Lyon</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospices Civils de Lyon</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Influenza is a major cause of morbidity and mortality. The investigators first goal is to
      evaluate soluble HLA-G5 isoform serum level as a potential marker of greater risk of death
      from Influenza respiratory illness in adult and pediatric patients hospitalized in
      reanimation. Secondly, the investigators collected respiratory samples in order to study the
      transcriptomic profiles of influenza-infected patients with severe symptoms.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 16, 2015</start_date>
  <completion_date type="Actual">January 2019</completion_date>
  <primary_completion_date type="Actual">January 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in ratio of the partial pressure of oxygen in arterial blood (PaO2) to the inspired oxygen fraction (FiO2), from admission at 7 days post-admission</measure>
    <time_frame>The first, third, fifth and seventh day of hospitalization in reanimation</time_frame>
    <description>decreased arterial PaO2/FiO2 ratio ≤ 100 mmHg (≤ 13.3 kPa)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>All cause mortality</measure>
    <time_frame>90 days after hospitalization</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Extracorporeal membrane oxygenation requirement</measure>
    <time_frame>90 days after hospitalization</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SOFA score (Adult) PELOD (Pediatric)</measure>
    <time_frame>The first, third, fifth and seventh day of hospitalization in reanimation</time_frame>
    <description>Elevated Score is considered as an evidence of clinical gravity</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">227</enrollment>
  <condition>Influenza</condition>
  <condition>Severe Respiratory Infection</condition>
  <arm_group>
    <arm_group_label>influenza cohort</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Influenza is a major cause of morbidity and mortality. The investigators' first goal is to evaluate soluble HLA-G5 isoform serum level as a potential marker of greater risk of death from Influenza respiratory illness in adult and pediatric patients hospitalized in reanimation.
1 control group of 30 patients (ancillary study) will be constitued to have reference values of the HLA-G5 marker.
Secondly, the investigators collected respiratory samples in order to study the transcriptomic profiles of influenza-infected patients with severe symptoms.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>influenza cohort</intervention_name>
    <description>Influenza is a major cause of morbidity and mortality. The investigators' first goal is to evaluate soluble HLA-G5 isoform serum level as a potential marker of greater risk of death from Influenza respiratory illness in adult and pediatric patients hospitalized in reanimation. Secondly, the investigators collected respiratory samples in order to study the transcriptomic profiles of influenza-infected patients with severe symptoms.</description>
    <arm_group_label>influenza cohort</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient (Adult or Pediatric)

          -  Hospitalized in reanimation

          -  With a laboratory confirmed Influenza

          -  That agree to take part in the study

          -  Affiliated to National Health Insurance

        For ancillary group :

          -  Adult at least 60 years old

          -  Presenting at hospital for a blood test

        Exclusion Criteria:

          -  non willing to participate

          -  Influenza infection with no respiratory symptoms

          -  pregnancy

        For ancillary group :

          -  Presence of immunodepression defined by:

               -  Cancer, or cancer cured for less than 2 years

               -  Corticosteroids, Methotrexate (MTX), anti Tumor Necrosis Factor (TNF), anti-CD20

          -  Infection in progress (fever)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>1 Month</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jean-Sebastien CASALEGNO, MD/PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>HOSPICES CIVILS DE LYON, Virology Department</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Centre de Biologie et de Pathologie Nord</name>
      <address>
        <city>Lyon</city>
        <state>Rhone -alpes</state>
        <zip>69500</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Femme Mère Enfant</name>
      <address>
        <city>Bron</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU service réanimation adulte</name>
      <address>
        <city>Clermont Ferrand</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU service réanimation pédiatrique</name>
      <address>
        <city>Clermont Ferrand</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU service réanimation adulte</name>
      <address>
        <city>Dijon</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU service réanimation pédiatrique</name>
      <address>
        <city>Dijon</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU service réanimation adulte</name>
      <address>
        <city>Grenoble</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU service réanimation pédiatrique</name>
      <address>
        <city>Grenoble</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre de Biologie et Pathologie Est</name>
      <address>
        <city>Lyon</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital de la Croix Rousse-service réanimation adulte chirurgicale</name>
      <address>
        <city>Lyon</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital de la Croix Rousse-service réanimation adulte médicale</name>
      <address>
        <city>Lyon</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Edouard Herriot</name>
      <address>
        <city>Lyon</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Lyon Sud</name>
      <address>
        <city>Pierre Bénite</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Service de Réanimation Adulte</name>
      <address>
        <city>St Etienne</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Service de Réanimation Pédiatrique</name>
      <address>
        <city>St Etienne</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>February 2019</verification_date>
  <study_first_submitted>March 4, 2015</study_first_submitted>
  <study_first_submitted_qc>March 13, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 19, 2015</study_first_posted>
  <last_update_submitted>February 18, 2019</last_update_submitted>
  <last_update_submitted_qc>February 18, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">February 19, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Respiratory Tract Infections</mesh_term>
    <mesh_term>Influenza, Human</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

